Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)

Trial Profile

Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2018 New trial record
    • 20 Mar 2018 Results assessing efficacy of nilotinib (The data cutoff for data analysis was May 9, 2014) published in the Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top